Lv1
28 积分 2024-10-22 加入
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials
4天前
已完结
B cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies
5天前
已完结
Tissue-resident immune cells in the pathogenesis of multiple sclerosis
5天前
已完结
Prevalence and Impact of Bypassing or Overriding Phase 2 Trials in Neurologic Drug Development
25天前
已完结
From development to clinical success: the journey of established and next-generation BTK inhibitors
1个月前
已完结
Autoimmune encephalitis
1个月前
已完结
Autoimmune encephalitis
1个月前
已完结
RIPK2 as a promising druggable target for autoimmune diseases
2个月前
已完结
Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis
3个月前
已完结
Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study
3个月前
已完结
皖公网安备34019202002308
